Seizure protection by intrapulmonary delivery of midazolam in mice

Ashish Dhir, Dorota Zolkowska, Michael A Rogawski

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The lung provides a portal of entry that could be used to rapidly deliver anticonvulsant substances to the brain to treat seizures. In the present study, we demonstrate that midazolam, a water-soluble anticon-vulsant benzodiazepine, confers potent seizure protection when administered via the intrapulmonary route. High dose (100 mg/kg) intraperitoneal midazolam induced loss-of-righting reflex in mice. Lower doses of midazolam (100-1000 mg/kg) when administered intraperitoneally did not induce loss-of-righting reflex but protected animals against pentylenetetrazol (PTZ)-induced seizures. Intrapulmonary administration of midazolam via a tracheal cannula protected against intraperitoneal PTZ seizures at lower doses. The minimal intraperitoneal and intravenous doses of midazolam required to elevate the threshold for seizure signs induced by intravenous PTZ were 500 and 100 μg/kg, respectively, whereas the minimal intrapulmonary midazolam dose was 12.5 μg/kg. Intratracheal midazolam caused a large increase in intravenous PTZ threshold 5 min after administration but the effect declined rapidly over 60 min and no antiseizure activity was evident at 120 min. The minimal intraperitoneal doses of midazolam required to elevate the threshold for seizure signs induced by intravenous picrotoxin and kainic acid were 100 and 2000 μg/kg, respectively; the corresponding values for intratracheal midazolam were 25 and 100 μg/kg, respectively. We conclude that midazolam is a highly effective anticonvulsant when administered by the intrapulmonary route. Midazolam is substantially more potent when delivered into the lung than when administered intraperitoneally or intravenously. Inhalation could be an alternative to other routes of administration for the delivery of midazolam to rapidly abort acute seizures.

Original languageEnglish (US)
Pages (from-to)425-431
Number of pages7
JournalNeuropharmacology
Volume73
DOIs
StatePublished - 2013

Fingerprint

Midazolam
Seizures
Pentylenetetrazole
Righting Reflex
Anticonvulsants
Picrotoxin
Lung
Kainic Acid
Benzodiazepines
Inhalation

Keywords

  • Intratracheal administration
  • Kainic acid
  • Midazolam
  • Pentylenetetrazol
  • Picrotoxin
  • Pulmonary drug delivery
  • Seizures

ASJC Scopus subject areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Seizure protection by intrapulmonary delivery of midazolam in mice. / Dhir, Ashish; Zolkowska, Dorota; Rogawski, Michael A.

In: Neuropharmacology, Vol. 73, 2013, p. 425-431.

Research output: Contribution to journalArticle

Dhir, Ashish ; Zolkowska, Dorota ; Rogawski, Michael A. / Seizure protection by intrapulmonary delivery of midazolam in mice. In: Neuropharmacology. 2013 ; Vol. 73. pp. 425-431.
@article{fb1ea2b5df6d4c1faaaf85cb48270ae4,
title = "Seizure protection by intrapulmonary delivery of midazolam in mice",
abstract = "The lung provides a portal of entry that could be used to rapidly deliver anticonvulsant substances to the brain to treat seizures. In the present study, we demonstrate that midazolam, a water-soluble anticon-vulsant benzodiazepine, confers potent seizure protection when administered via the intrapulmonary route. High dose (100 mg/kg) intraperitoneal midazolam induced loss-of-righting reflex in mice. Lower doses of midazolam (100-1000 mg/kg) when administered intraperitoneally did not induce loss-of-righting reflex but protected animals against pentylenetetrazol (PTZ)-induced seizures. Intrapulmonary administration of midazolam via a tracheal cannula protected against intraperitoneal PTZ seizures at lower doses. The minimal intraperitoneal and intravenous doses of midazolam required to elevate the threshold for seizure signs induced by intravenous PTZ were 500 and 100 μg/kg, respectively, whereas the minimal intrapulmonary midazolam dose was 12.5 μg/kg. Intratracheal midazolam caused a large increase in intravenous PTZ threshold 5 min after administration but the effect declined rapidly over 60 min and no antiseizure activity was evident at 120 min. The minimal intraperitoneal doses of midazolam required to elevate the threshold for seizure signs induced by intravenous picrotoxin and kainic acid were 100 and 2000 μg/kg, respectively; the corresponding values for intratracheal midazolam were 25 and 100 μg/kg, respectively. We conclude that midazolam is a highly effective anticonvulsant when administered by the intrapulmonary route. Midazolam is substantially more potent when delivered into the lung than when administered intraperitoneally or intravenously. Inhalation could be an alternative to other routes of administration for the delivery of midazolam to rapidly abort acute seizures.",
keywords = "Intratracheal administration, Kainic acid, Midazolam, Pentylenetetrazol, Picrotoxin, Pulmonary drug delivery, Seizures",
author = "Ashish Dhir and Dorota Zolkowska and Rogawski, {Michael A}",
year = "2013",
doi = "10.1016/j.neuropharm.2013.06.002",
language = "English (US)",
volume = "73",
pages = "425--431",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Seizure protection by intrapulmonary delivery of midazolam in mice

AU - Dhir, Ashish

AU - Zolkowska, Dorota

AU - Rogawski, Michael A

PY - 2013

Y1 - 2013

N2 - The lung provides a portal of entry that could be used to rapidly deliver anticonvulsant substances to the brain to treat seizures. In the present study, we demonstrate that midazolam, a water-soluble anticon-vulsant benzodiazepine, confers potent seizure protection when administered via the intrapulmonary route. High dose (100 mg/kg) intraperitoneal midazolam induced loss-of-righting reflex in mice. Lower doses of midazolam (100-1000 mg/kg) when administered intraperitoneally did not induce loss-of-righting reflex but protected animals against pentylenetetrazol (PTZ)-induced seizures. Intrapulmonary administration of midazolam via a tracheal cannula protected against intraperitoneal PTZ seizures at lower doses. The minimal intraperitoneal and intravenous doses of midazolam required to elevate the threshold for seizure signs induced by intravenous PTZ were 500 and 100 μg/kg, respectively, whereas the minimal intrapulmonary midazolam dose was 12.5 μg/kg. Intratracheal midazolam caused a large increase in intravenous PTZ threshold 5 min after administration but the effect declined rapidly over 60 min and no antiseizure activity was evident at 120 min. The minimal intraperitoneal doses of midazolam required to elevate the threshold for seizure signs induced by intravenous picrotoxin and kainic acid were 100 and 2000 μg/kg, respectively; the corresponding values for intratracheal midazolam were 25 and 100 μg/kg, respectively. We conclude that midazolam is a highly effective anticonvulsant when administered by the intrapulmonary route. Midazolam is substantially more potent when delivered into the lung than when administered intraperitoneally or intravenously. Inhalation could be an alternative to other routes of administration for the delivery of midazolam to rapidly abort acute seizures.

AB - The lung provides a portal of entry that could be used to rapidly deliver anticonvulsant substances to the brain to treat seizures. In the present study, we demonstrate that midazolam, a water-soluble anticon-vulsant benzodiazepine, confers potent seizure protection when administered via the intrapulmonary route. High dose (100 mg/kg) intraperitoneal midazolam induced loss-of-righting reflex in mice. Lower doses of midazolam (100-1000 mg/kg) when administered intraperitoneally did not induce loss-of-righting reflex but protected animals against pentylenetetrazol (PTZ)-induced seizures. Intrapulmonary administration of midazolam via a tracheal cannula protected against intraperitoneal PTZ seizures at lower doses. The minimal intraperitoneal and intravenous doses of midazolam required to elevate the threshold for seizure signs induced by intravenous PTZ were 500 and 100 μg/kg, respectively, whereas the minimal intrapulmonary midazolam dose was 12.5 μg/kg. Intratracheal midazolam caused a large increase in intravenous PTZ threshold 5 min after administration but the effect declined rapidly over 60 min and no antiseizure activity was evident at 120 min. The minimal intraperitoneal doses of midazolam required to elevate the threshold for seizure signs induced by intravenous picrotoxin and kainic acid were 100 and 2000 μg/kg, respectively; the corresponding values for intratracheal midazolam were 25 and 100 μg/kg, respectively. We conclude that midazolam is a highly effective anticonvulsant when administered by the intrapulmonary route. Midazolam is substantially more potent when delivered into the lung than when administered intraperitoneally or intravenously. Inhalation could be an alternative to other routes of administration for the delivery of midazolam to rapidly abort acute seizures.

KW - Intratracheal administration

KW - Kainic acid

KW - Midazolam

KW - Pentylenetetrazol

KW - Picrotoxin

KW - Pulmonary drug delivery

KW - Seizures

UR - http://www.scopus.com/inward/record.url?scp=84885132965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885132965&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2013.06.002

DO - 10.1016/j.neuropharm.2013.06.002

M3 - Article

VL - 73

SP - 425

EP - 431

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -